Teladoc Health Relocates Principal Executive Offices
Ticker: TDOC · Form: 8-K · Filed: Oct 30, 2024 · CIK: 1477449
| Field | Detail |
|---|---|
| Company | Teladoc Health, Inc. (TDOC) |
| Form Type | 8-K |
| Filed Date | Oct 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing-update
Related Tickers: TDOC
TL;DR
TDOC moved its HQ to Purchase, NY effective Oct 30, 2024.
AI Summary
On October 30, 2024, Teladoc Health, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2 Manhattanville Road, Suite 203, Purchase, NY 10577. This move is effective as of October 30, 2024.
Why It Matters
A change in principal executive offices can signal operational shifts or strategic realignments within a company. Investors should monitor if this move impacts operational efficiency or costs.
Risk Assessment
Risk Level: low — This filing primarily concerns a change of address for the company's principal executive offices, which typically carries low risk.
Key Players & Entities
- Teladoc Health, Inc. (company) — Registrant
- 2 Manhattanville Road, Suite 203, Purchase, NY 10577 (location) — New Principal Executive Offices
- October 30, 2024 (date) — Effective date of address change
FAQ
What is the new address for Teladoc Health, Inc.'s principal executive offices?
The new address for Teladoc Health, Inc.'s principal executive offices is 2 Manhattanville Road, Suite 203, Purchase, NY 10577.
When did this change of address become effective?
The change of address became effective on October 30, 2024.
Is this filing related to a merger or acquisition?
No, this filing (Form 8-K) is specifically reporting a change in the company's principal executive offices and does not mention any merger or acquisition activity.
What was the previous address of Teladoc Health, Inc.'s principal executive offices?
The filing does not explicitly state the previous address, only the new address.
What is the Commission File Number for Teladoc Health, Inc.?
The Commission File Number for Teladoc Health, Inc. is 001-37477.
Filing Stats: 503 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-10-30 16:11:34
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share TDOC The New York Stock Excha
Filing Documents
- tdoc-20241030.htm (8-K) — 27KB
- tdoc-20240930xexx991.htm (EX-99.1) — 391KB
- image_0a.jpg (GRAPHIC) — 6KB
- 0001477449-24-000224.txt ( ) — 578KB
- tdoc-20241030.xsd (EX-101.SCH) — 2KB
- tdoc-20241030_lab.xml (EX-101.LAB) — 22KB
- tdoc-20241030_pre.xml (EX-101.PRE) — 13KB
- tdoc-20241030_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 30, 2024, Teladoc Health, Inc. (the "Company") issued a press release relating to its financial results for the third quarter of 2024. A copy of the press release, which is incorporated by reference herein, is attached hereto as Exhibit 99.1. The foregoing information (including the exhibit set forth in Item 9.01 hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1* Teladoc Health, Inc. press release, dated October 3 0 , 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Furnished herewith. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2024 Teladoc Health, Inc. By: /s/ Adam C. Vandervoort Name: Adam C. Vandervoort Title: Chief Legal Officer and Secretary